Skip to main content
Top
Published in: Acta Neurologica Belgica 2/2017

01-06-2017 | Original Article

Potential risk factors for vitamin D levels in medium- and long-term use of antiepileptic drugs in childhood

Authors: Edibe Pempegül Yildiz, Şükran Poyrazoglu, Gonca Bektas, Aslı Derya Kardelen, Nur Aydinli

Published in: Acta Neurologica Belgica | Issue 2/2017

Login to get access

Abstract

Antiepileptic drugs (AED) have potential side effects through vitamin-D. Prevalence of vitamin D insufficiency and potential risk factors for the longitudinal changes of vitamin D levels compared to its baseline levels under AED treatment were investigated in this study. This retrospective study includes patients whose AED therapy were started in only autumn months, between 2000 and 2014. Detailed assessment of neurologic diagnosis and brain MRI findings, ambulatory status, types and durations of AED treatment, and baseline bone health blood tests (vitamin-D, alkaline phosphatase, calcium, and phosphate levels) were obtained on all patients. Vitamin-D deficiency was defined as 25(OH)D <20 ng/mL, while vitamin-D insufficiency was defined as 25(OH)D between 21 and 29 ng/mL. A total of 172 children (mean age 9.6 ± 4.3 years) were followed up 5.3 years in average (range 1–14.7). The mean baseline 25(OH)D level was decreased from 24.4 ± 11.6 to 19.6 ± 10.7 ng/mL at the last follow up. The mean change in the vitamin-D levels (ΔD-vitamin) was −4.8 ng/mL (p = 0.003). The rate of vitamin-D deficiency was 54% and insufficiency was 25%. Multivariate logistic regression analysis identified only long-term use of AEDs as a risk factor for the longitudinal decrease. Monotherapy with valproic acid (n = 45), carbamazepine (n = 20), levetiracetam (n = 10) and phenobarbital (n = 12) was compared with each other. There was no difference in terms of longitudinal changes in 25(OH)D levels. In the treatment of childhood epilepsy, 25(OH)D levels should be monitored, especially when long-term AED used, in order to prevent D-hypovitaminosis.
Literature
2.
go back to reference Saggese G, Vierucci F, Boot AM, Czech-Kowalska J, Weber G, Camargo CA Jr et al (2015) Vitamin D in childhood and adolescence: an expert position statement. Eur J Pediatr 174:565–576CrossRefPubMed Saggese G, Vierucci F, Boot AM, Czech-Kowalska J, Weber G, Camargo CA Jr et al (2015) Vitamin D in childhood and adolescence: an expert position statement. Eur J Pediatr 174:565–576CrossRefPubMed
3.
go back to reference Shellhaas RA, Joshi SM (2010) Vitamin D and bone health among children with epilepsy. Pediatr Neurol 42:385–393CrossRefPubMed Shellhaas RA, Joshi SM (2010) Vitamin D and bone health among children with epilepsy. Pediatr Neurol 42:385–393CrossRefPubMed
4.
go back to reference Medicines and Healthcare products Regulatory Agency (MHRA), Commission on Human Medicines (CHM (2009) Drug safety advice antiepileptics: adverse effects on bone. Drug Saf Update. 2:2 Medicines and Healthcare products Regulatory Agency (MHRA), Commission on Human Medicines (CHM (2009) Drug safety advice antiepileptics: adverse effects on bone. Drug Saf Update. 2:2
5.
go back to reference Cebeci AN, Ekici B (2014) Epilepsy treatment by sacrificing vitamin D. Expert Rev Neurother 14:481–491CrossRefPubMed Cebeci AN, Ekici B (2014) Epilepsy treatment by sacrificing vitamin D. Expert Rev Neurother 14:481–491CrossRefPubMed
6.
7.
go back to reference Shevell M, Ashwal S, Donley D, Flint J, Gingold M, Hirtz D, Majnemer A, Noetzel M, Sheth RD (2003) Quality Standards Subcommittee of the American Academy of N, Practice Committee of the Child Neurology S. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology. 60:367–380CrossRefPubMed Shevell M, Ashwal S, Donley D, Flint J, Gingold M, Hirtz D, Majnemer A, Noetzel M, Sheth RD (2003) Quality Standards Subcommittee of the American Academy of N, Practice Committee of the Child Neurology S. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology. 60:367–380CrossRefPubMed
8.
go back to reference Erol M, Yiğit Ö, Küçük SH, Bostan Gayret Ö (2015) Vitamin D Deficiency in Children and Adolescents in Bağcılar, Istanbul. J Clin Res Pediatr Endocrinol. 7(2):134–139CrossRefPubMedPubMedCentral Erol M, Yiğit Ö, Küçük SH, Bostan Gayret Ö (2015) Vitamin D Deficiency in Children and Adolescents in Bağcılar, Istanbul. J Clin Res Pediatr Endocrinol. 7(2):134–139CrossRefPubMedPubMedCentral
10.
go back to reference Bergqvist AG, Schall JI, Stallings VA (2007) Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia 48:66–71CrossRefPubMed Bergqvist AG, Schall JI, Stallings VA (2007) Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia 48:66–71CrossRefPubMed
11.
go back to reference Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC (2006) Use of antiepileptic drugs and risk of fractures: case–control study among patients with epilepsy. Neurology 66:1318–1324CrossRefPubMed Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC (2006) Use of antiepileptic drugs and risk of fractures: case–control study among patients with epilepsy. Neurology 66:1318–1324CrossRefPubMed
12.
go back to reference Baek JH, Seo YH, Kim GH, Kim MK, Eun BL (2014) Vitamin D levels in children and adolescents with antiepileptic drug treatment. Yonsei Med J 55:417–421CrossRefPubMedPubMedCentral Baek JH, Seo YH, Kim GH, Kim MK, Eun BL (2014) Vitamin D levels in children and adolescents with antiepileptic drug treatment. Yonsei Med J 55:417–421CrossRefPubMedPubMedCentral
13.
go back to reference Lee YJ, Park KM, Kim YM, Yeon GM, Nam SO (2015) Longitudinal change of vitamin D status in children with epilepsy on antiepileptic drugs: prevalence and risk factors. Pediatr Neurol 52:153–159CrossRefPubMed Lee YJ, Park KM, Kim YM, Yeon GM, Nam SO (2015) Longitudinal change of vitamin D status in children with epilepsy on antiepileptic drugs: prevalence and risk factors. Pediatr Neurol 52:153–159CrossRefPubMed
14.
go back to reference Nettekoven S, Strohle A, Trunz B, Wolters M, Hoffmann S, Horn R et al (2008) Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. Eur J Pediatr 167:1369–1377CrossRefPubMed Nettekoven S, Strohle A, Trunz B, Wolters M, Hoffmann S, Horn R et al (2008) Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. Eur J Pediatr 167:1369–1377CrossRefPubMed
15.
go back to reference El-Hajj Fuleihan G, Dib L, Yamout B, Sawaya R, Mikati MA (2008) Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone 43:149–155CrossRefPubMed El-Hajj Fuleihan G, Dib L, Yamout B, Sawaya R, Mikati MA (2008) Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone 43:149–155CrossRefPubMed
16.
go back to reference Bell RD, Pak CY, Zerwekh J, Barilla DE, Vasko M (1979) Effect of phenytoin on bone and vitamin D metabolism. Ann Neurol 5:374–378CrossRefPubMed Bell RD, Pak CY, Zerwekh J, Barilla DE, Vasko M (1979) Effect of phenytoin on bone and vitamin D metabolism. Ann Neurol 5:374–378CrossRefPubMed
17.
go back to reference Mintzer S, Boppana P, Toguri J, DeSantis A (2006) Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 47:510–515CrossRefPubMed Mintzer S, Boppana P, Toguri J, DeSantis A (2006) Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 47:510–515CrossRefPubMed
18.
go back to reference Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M (2008) Drug, Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine S. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 122:398–417CrossRefPubMed Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M (2008) Drug, Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine S. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 122:398–417CrossRefPubMed
19.
go back to reference Cansu A, Yesilkaya E, Serdaroglu A, Hirfanoglu TL, Camurdan O, Gulbahar O et al (2008) Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol 39:266–271CrossRefPubMed Cansu A, Yesilkaya E, Serdaroglu A, Hirfanoglu TL, Camurdan O, Gulbahar O et al (2008) Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol 39:266–271CrossRefPubMed
20.
go back to reference Vanlint S, Nugent M, Durvasula S (2008) Vitamin D and people with intellectual disability. Aust Fam Phys 37:348–351 Vanlint S, Nugent M, Durvasula S (2008) Vitamin D and people with intellectual disability. Aust Fam Phys 37:348–351
21.
go back to reference Babayigit A, Dirik E, Bober E, Cakmakci H (2006) Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 35:177–181CrossRefPubMed Babayigit A, Dirik E, Bober E, Cakmakci H (2006) Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 35:177–181CrossRefPubMed
Metadata
Title
Potential risk factors for vitamin D levels in medium- and long-term use of antiepileptic drugs in childhood
Authors
Edibe Pempegül Yildiz
Şükran Poyrazoglu
Gonca Bektas
Aslı Derya Kardelen
Nur Aydinli
Publication date
01-06-2017
Publisher
Springer International Publishing
Published in
Acta Neurologica Belgica / Issue 2/2017
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-017-0775-x

Other articles of this Issue 2/2017

Acta Neurologica Belgica 2/2017 Go to the issue